How Cognitive Bias Undermines Value Creation in Life Sciences M&A
Life Sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters.
How Cognitive Bias Undermines Value Creation in Life Sciences M&A
Published in In Vivo, September 2017
Author: Oded Ben-Joseph, Ph.D.
Life Sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters, but the cognitive biases inherent in subjective assessments can derail deals. Executives need to take emotion out of the equation and rely on relevant data to craft successful transactions.
Mergers and acquisition transactions play a central role in the life sciences sector and are the catalyst for growth and transformation, driving innovation from the laboratory all the way to the patient. Life sciences companies often fall victim to recurring misconceptions that lead to unnecessary failure.
News
Outcome Capital Continues to Expand with the Addition of Charles Simmons
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreResources
Outcome Capital Life Science Market Pulse, November 2024
Outcome Capital Life Science Market Pulse November 2024 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
